UK Court Sides With Pfizer, BioNTech in MRNA Patent Case Against CureVac
Express News | Pfizer (PFE.N) and the German biotechnology company BioNTech have won a lawsuit in the United Kingdom court, successfully invalidating CureVac's patent on mRNA technology in the COVID-19 vaccine.
Express News | Pfizer, BioNTech Win Bid in UK Court to Invalidate CureVac's Patents Over Mrna Technology in Covid-19 Vaccines
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
CureVac N.V.'s (NASDAQ:CVAC) Top Owners Are Individual Investors With 35% Stake, While 31% Is Held by Private Equity Firms
JMP Securities Reiterates Market Outperform on CureVac, Maintains $16 Price Target
JMP Securities Maintains CureVac(CVAC.US) With Buy Rating, Maintains Target Price $16
JMP Securities analyst Roy Buchanan maintains $CureVac(CVAC.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 25.8% and a
CureVac's Promising Cancer Vaccine Candidate CVGBM Elicits Buy Rating
CureVac Shares Are Trading Higher After the Company Presented Its CVGBM Cancer Vaccine Results From Its Phase 1 Study of Glioblastoma at the ESMO 2024 Congress.
GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza MRNA Vaccine
GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal
GSK, CureVac MRNA Flu Shot Reaches Late-stage Studies
Express News | CureVac NV Says : CureVac Partner GSK Announces Positive Phase 2 Data From Seasonal Influenza Mrna Vaccine Program
CureVac Unveils Promising Glioblastoma Vaccine Data
Deutsche Bank Maintains CureVac(CVAC.US) With Hold Rating, Cuts Target Price to $3.9
Deutsche Bank analyst Emmanuel Papadakis maintains $CureVac(CVAC.US)$ with a hold rating, and adjusts the target price from $5 to $3.9.According to TipRanks data, the analyst has a success rate of 57.
CureVac (CVAC) Receives a Hold From Deutsche Bank
We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely
Analysts Offer Insights on Healthcare Companies: CureVac (CVAC), Vericel (VCEL) and Twist Bioscience (TWST)
CureVac Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
JMP Securities Maintains Market Outperform on CureVac, Lowers Price Target to $16